Application of recombinant DcR3-SUMO protein in medicine for treating sepsis
Through the use of recombinant DcR3-SUMO protein, the problem of cumbersome production process and small yield in sepsis treatment was solved, and efficient anti-inflammatory and therapeutic effects were achieved, reducing the mortality rate and inflammatory factors of septic mice. Expression and improves organ damage.
Patent Information
- Application Number
- CN202410916718.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatments for sepsis have not effectively reduced the long-term mortality rate, and the production process of DcR3 protein is cumbersome and has small yields. It is necessary to develop a substance that replaces DcR3 protein to simplify the production process and maintain anti-inflammatory and therapeutic effects.
The recombinant DcR3-SUMO protein was expressed and purified in vitro by the E. coli prokaryotic expression system, providing higher yields and simplifying the production process, and was used in the treatment of sepsis through intraperitoneal infusion.
Recombinant DcR3-SUMO protein can effectively reduce the mortality rate, reduce the expression of inflammatory factors in septic mice, and reduce organ damage, showing significant anti-inflammatory and therapeutic effects.
Smart Images

Figure CN118903376A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of new drug applications, and particularly relates to an application of a recombinant DcR3-SUMO protein in a drug for treating sepsis. Background Art
[0002] Sepsis refers to life-threatening organ dysfunction caused by an imbalanced immune response in patients due to infection. So far, no specific drug has been found to effectively cure sepsis. Sepsis has the significant characteristics of high morbidity, high mortality, high economic burden and high poor prognosis. As a global disease, sepsis has been listed as a global health priority by the World Health Organization in 2017. With the aging of the population, sepsis accompanied by various complications will bring greater economic burden to the world. Many drug attempts have been made for the treatment of sepsis, but none of them have achieved satisfactory results. Only early prevention, early detection and early treatment can reduce the morbidity and improve the survival rate of sepsis patients. The treatment of sepsis mainly focuses on fluid resuscitation, antibiotic treatment and immunotherapy. Although the short-term mortality rate of sepsis can be significantly reduced after treatment with the above schemes, its long-term mortality rate remains high.
[0003] Decoy receptor 3 (DcR3), also known as TNFRSF6B, TR6 or M68, belongs to the decoy receptor family in the tumor necrosis factor receptor superfamily. It is a soluble receptor lacking a transmembrane domain and is chemically a glycosylated protein. The DcR3 gene was first identified and named by Pitti et al. in 1998. DcR3 protein was found to be highly expressed in the serum of patients with various malignant tumors. The DcR3 gene exists in many species except rats and mice. The human DcR3 gene is located at the telomere end of chromosome 20 and encodes 300 amino acids, of which the first 29 amino acid residues are signal peptide sequences, and the mature product is about 33 kilodaltons in size. At present, the physiological role of DcR3 is not fully understood, but as a soluble receptor in the decoy receptor family, DcR3 can play a decoy function by blocking the original biological effects of FasL, LIGHT and TL1A. In addition, DcR3 can also play a non-deceptive function by binding to heparan sulfate proteoglycan (HSPG), regulating macrophage differentiation to M2, regulating Th1 / Th2 cells to Th2 differentiation, and promoting monocyte cell adhesion. In recent years, it has been found that the expression of DcR3 is significantly upregulated in sepsis, and DcR3 can be used as a biomarker for sepsis. However, whether upregulated DcR3 has a regulatory effect on inflammatory cells remains to be further clarified.
[0004] The Chinese patent application number CN201510133480.3 discloses the use of a decoy receptor 3 in a drug for treating sepsis. DcR3 is expressed in the serum of sepsis patients and is associated with the mortality rate of sepsis. DcR3 is involved in the occurrence and development of sepsis. DcR3 can reduce the mortality rate of septic mice, reduce the inflammatory response of septic mice, inhibit the apoptosis of lymphocytes in septic mice, and protect the functions of organs such as the liver and lungs. Therefore, DcR3 has a certain therapeutic effect on sepsis. However, the production process of DcR3 protein is cumbersome and the output is small. At present, a substance that can replace DcR3 protein still needs to be developed.
[0005] The DcR3-SUMO protein (49 kDa) is an analog of DcR3 (31 kDa). Structurally, DcR3-SUMO differs from DcR3 by the presence of the His-SUMO sequence. In vitro expressed and purified DcR3-SUMO provides higher yields and a simplified production process compared to DcR3 protein. The yield of DcR3-SUMO protein is approximately four times that of DcR3. However, whether DcR3-SUMO retains the anti-inflammatory and therapeutic effects of DcR3 in sepsis is unknown. Summary of the invention
[0006] In order to solve the above problems, the present invention provides an application of a recombinant DcR3-SUMO protein in a drug for treating sepsis.
[0007] The technical solution of the present invention is as follows:
[0008] Application of a recombinant DcR3-SUMO protein in a drug for treating sepsis.
[0009] Furthermore, the medicine is an injectable preparation.
[0010] Furthermore, the injection preparation is administered by intraperitoneal infusion.
[0011] Furthermore, the nucleic acid sequence of the recombinant DcR3-SUMO protein gene is shown in SEQ ID NO.1.
[0012] Furthermore, the amino acid sequence of the recombinant DcR3-SUMO protein gene is shown in SEQ ID NO.2.
[0013] Compared with the prior art, the present invention has the following beneficial effects: the present invention provides an application of a recombinant DcR3-SUMO protein in a drug for treating sepsis, wherein the recombinant DcR3-SUMO protein can effectively treat septic mice, reduce the mortality of septic mice, reduce the expression of inflammatory factors in septic mice, and alleviate organ damage in septic mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is the plasmid map of the DcR3-SUMO protein expression vector in the present invention;
[0015] Figure 2 This is a schematic diagram of the effects of different concentrations of DcR3-SUMO and DcR3 empty protein on RAW264.7 cells in the present invention;
[0016] Figure 3 This is a schematic diagram of the effects of different concentrations of DcR3-SUMO and DcR3 empty protein on THP1 cells in the present invention;
[0017] Figure 4 Schematic diagram to demonstrate that DcR3-SUMO can effectively treat LPS-induced sepsis in mice;
[0018] Figure 5 Schematic diagram to prove that DcR3-SUMO can significantly reduce the expression of inflammatory factors in LPS-induced septic mice;
[0019] Figure 6 Schematic diagram showing that DcR3-SUMO can effectively improve organ damage in LPS-induced septic mice. DETAILED DESCRIPTION
[0020] The following is in conjunction with the preferred embodiment and with reference to the attached Figure 1-6 , the present invention is further described. The endpoints and any values of the ranges disclosed in the present invention are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values; for numerical ranges, the endpoint values of each range, the endpoint values of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed herein; the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial channels; the experimental methods in the following examples, unless otherwise specified, are all conventional methods.
[0021] The E. coli BL21 (DE3) competent cells involved in the following examples were derived from Beijing Quanshijin Biotechnology Co., Ltd., and the DcR3 in vitro E. coli prokaryotic expression plasmid was constructed by the laboratory (Southern Biomedical Research Center, Fujian Normal University) and subsequently synthesized by General Biosystems (Anhui) Co., Ltd.
[0022] Example 1
[0023] Production process of DcR3-SUMO protein
[0024] S1: Insert the DcR3 cDNA sequence into the pSmart-I vector to construct a DcR3-SUMO expression vector with restriction sites of BamHI and XhoI;
[0025] S2: Transform the DcR3-SUMO expression vector into BL21(DE3) competent cells to construct a DcR3 protein expression strain;
[0026] S3: Use antibiotic-kanamycin to pick single colonies, and expand the culture of the correctly identified colonies;
[0027] S4: Use IPTG to induce DcR3-SUMO protein expression;
[0028] S5: Purification and identification of DcR3-SUMO protein.
[0029] Example 2
[0030] In vitro investigation of the anti-inflammatory effect of DcR3-SUMO
[0031] In this example, DcR3 expression was used as a negative control, and RAW264.7 cells and THP1 cells were pre-treated with DcR3-SUMO, and then stimulated with 1 μg / mL LPS for 3 h. The test results are shown in Figure 2. Figure 2-3 shown.
[0032] Figure 2 Schematic diagram of the effects of different concentrations of DcR3-SUMO and DcR3 empty protein on RAW264.7 cells. Figure 2 In the figure, A is a schematic diagram showing the effect of different concentrations of DcR3-SUMO treatment for 24 hours on the viability of RAW264.7 cells, B is a schematic diagram showing the effect of DcR3 empty protein treatment for 48 hours on LPS-induced intracellular inflammatory factors in RAW264.7 cells, C is a schematic diagram showing the effect of DcR3 empty protein treatment for 72 hours on LPS-induced intracellular inflammatory factors in RAW264.7 cells, DF are the expression levels of intracellular inflammatory factors mRNA levels after RAW264.7 cells were pretreated with DcR3-SUMO protein for 48 hours and LPS stimulated the cells for 3 hours, D is IL-1β, E is IL-6, and F is TNF-α; GI is the expression levels of intracellular inflammatory factors mRNA levels after RAW264.7 cells were pretreated with DcR3-SUMO protein for 72 hours and LPS stimulated the cells for 3 hours, G is IL-1β, H is IL-6, and I is TNF-α.
[0033] like Figure 2 As shown in Figure A, treatment of RAW264.7 cells with 0.2-1.6 μg / mL DcR3-SUMO for 24 h did not cause a significant decrease in RAW264.7 cell viability; Figure 2 As shown in Figure BC, compared with the LPS group, treatment of RAW264.7 cells with 0.2-0.8 μg / mL DcR3 empty protein for 48 h and 72 h did not significantly reduce the expression level of IL-1β mRNA. Figure 1 As shown in Figure DI, compared with the LPS group, treatment of RAW264.7 cells with 0.2-0.4 μg / mL DcR3-SUMO for 48 h and 72 h could significantly reduce the mRNA expression levels of IL-1β, IL-6 and TNF-α.
[0034] Figure 3 Schematic diagram of the effects of different concentrations of DcR3-SUMO and DcR3 empty protein on THP1 cells. Figure 3 In the figure, A is a schematic diagram showing the effect of different concentrations of DcR3-SUMO treatment for 24 hours on the viability of THP1 cells, B is a schematic diagram showing the effect of DcR3 empty protein treatment for 3 hours on LPS-induced intracellular inflammatory factors in THP1 cells; C is a schematic diagram showing the effect of DcR3 empty protein treatment for 6 hours on LPS-induced intracellular inflammatory factors in THP1 cells; DF is the expression of intracellular inflammatory factor mRNA levels after THP1 cells were pretreated with DcR3-SUMO protein for 3 hours and LPS stimulated the cells for 3 hours, D is IL-1β, E is IL-6, and F is TNF-α; GI is the expression of intracellular inflammatory factor mRNA levels after THP1 cells were pretreated with DcR3-SUMO protein for 6 hours and LPS stimulated the cells for 3 hours, G is IL-1β, H is IL-6, and I is TNF-α.
[0035] like Figure 3 As shown in A, DcR3-SUMO stimulation of THP1 cells at a concentration of 0.2-1.6 mg / mL for 24 h did not cause a significant decrease in cell viability; Figure 3 As shown in BC, compared with the LPS group, treatment of THP1 cells with DcR3 empty protein at a concentration of 0.2-0.8 mg / mL for 3 h and 6 h did not significantly reduce the expression level of IL-1β mRNA; Figure 3 As shown in Figure DI, compared with the LPS group, treatment of THP1 cells with DcR3-SUMO at a concentration of 0.2-0.8 mg / mL for 3h and 6h could significantly reduce the expression levels of IL-1β and TNF-α mRNA.
[0036] Example 3
[0037] In this example, a sepsis mouse model was used to explore the anti-inflammatory effect of DcR3-SUMO in vivo, with DcR3 as a positive control group.
[0038] Figure 4Schematic diagram showing that DcR3-SUMO can effectively treat LPS-induced sepsis in mice. Figure 4 As shown, A is the dosing and observation timeline of mice. The drug was administered by intraperitoneal injection. DcR3-SUMO or DcR3 protein was injected three days in advance at a protein dose of 1 mg / kg / day. The drug was administered continuously for 3 days. A timer was set 0.5 h after the last dose. LPS was then injected intraperitoneally at a dose of 15 mg / kg. This time was recorded as 0 h, and the mice were killed 12 h later.
[0039] Grouping: The mice were divided into: Mock group (10 mice), LPS group (14 mice), DcR3-SUMO+LPS group (10 mice) and DcR3+LPS group (10 mice). The Mock group consisted of mice that were not specially treated and were fed under normal conditions.
[0040] B is a diagram of the mouse status within 12 hours, C is a diagram of the mouse status score, D is a schematic diagram of the effect of DcR3-SUMO on the survival rate of mice, and E is a schematic diagram of the effect of DcR3-SUMO on the survival rate of mice with LPS-induced sepsis.
[0041] During the experiment, it was observed that 12 hours after LPS stimulation, the mice in the Mock group moved normally, scattered around the cage, had shiny hair, could eat normally, and were sensitive to external stimuli; the mice in the LPS group gathered in a corner of the cage, had limited movement, had erect hair, had significantly reduced eating frequency, had white secretions in their eyes, and had a weakened response to external stimuli; the mice in the DcR3-SUMO and DcR3 groups moved normally in the cage, scattered around the cage, had shiny hair, could eat normally, had no white secretions in their eyes, and were sensitive to external stimuli. Figure 4 As shown in Figure C, both DcR3-SUMO and DcR3 administration can significantly improve the morphological changes of mice, and no significant difference was found in the morphological improvement between the two, indicating that there is no significant difference in the anti-inflammatory function between DcR3-SUMO and DcR3. Figure 4 As shown in Figure D, during the 10-day observation period, neither DcR3-SUMO nor DcR3 treatment caused the death of mice, indicating that the dose used in this example is a safe dose. Figure 4 As shown in E, all mice in the LPS group died at 36 h, and the difference was significant compared with the Mock group (P<0.0001); both DcR3-SUMO and DcR3 could significantly increase the survival rate of LPS-induced sepsis mice (50%) (P<0.0001), and there was no significant difference between the two (P>0.05).
[0042] Example 4
[0043] This example uses a sepsis mouse model to explore the effect of DcR3-SUMO on the expression of inflammatory factors in LPS-induced sepsis mice.
[0044] Figure 5 Schematic diagram to prove that DcR3-SUMO can significantly reduce the expression of inflammatory factors in LPS-induced septic mice, as shown in Figure 5 As shown, A is a schematic diagram of drug administration and sampling in mice, BD is a schematic diagram of the effect of DcR3-SUMO on serum inflammatory factors in LPS-induced septic mice, and EL is a schematic diagram of the effect of DcR3-SUMO on organ inflammatory factors in LPS-induced septic mice.
[0045] The drug administration and sampling time nodes of this embodiment are as follows Figure 5 As shown in A, the drug was administered by intraperitoneal injection. DcR3-SUMO or DcR3 protein was injected three days in advance at a protein dosage of 1 mg / kg / day. The drug was administered continuously for 3 days. A time was set 0.5 h after the last administration. LPS was then intraperitoneally injected at a dosage of 15 mg / kg. This time was recorded as 0 h. The mice were killed 12 h later, and peripheral blood, liver, lung and other tissues and organs of the mice were collected.
[0046] Grouping: The mice were divided into: Mock group (10 mice), LPS group (14 mice), DcR3-SUMO+LPS group (10 mice) and DcR3+LPS group (10 mice)
[0047] The mice used in this example are all C57BL / 6J without specific pathogens, sourced from Shanghai Slake Company. The feeding conditions for the mouse experiment are: room temperature 23-25°C, humidity 40%-60%, day and night alternation every 12 hours, free access to food and water, and a density of 3-5 mice per cage. All experiments used 8-10 week old mice, half male and half female. A week of adaptive feeding was performed before the mouse experiment, and all animal experiments were carried out in strict accordance with the laboratory animal care and use guidelines approved by the Fujian Provincial Laboratory Animal Management Office and the Animal Care and Committee of Fujian Normal University (Approval No. 20180013).
[0048] like Figure 5 As shown in BD, compared with the Mock group, LPS stimulation for 12h resulted in a significant increase in the serum protein levels of IL-1β, IL-6, and TNF-α (P<0.0001); compared with the LPS group, both DcR3-SUMO and DcR3 treatments could significantly reduce the serum protein levels of IL-1β, IL-6, and TNF-α (P<0.0001), and there was no significant difference between DcR3-SUMO and DcR3 in reducing the expression levels of serum IL-6 and TNF-α (P>0.05). Figure 5As shown in the middle EL, compared with the LPS group, the mRNA expression of IL-1β, IL-6 and TNF-α in the liver and lung tissues of the DcR3-SUMO and DcR3 treatment groups was significantly decreased (P<0.01). In the tissues where inflammatory factors decreased, the effects of DcR3-SUMO and DcR3 treatment were consistent, with no significant difference (P>0.05). In addition, DcR3-SUMO treatment caused a significant increase in the mRNA expression of IL-10 in the liver and lung tissues (P<0.05).
[0049] Figure 6 Schematic diagram to prove that DcR3-SUMO can effectively improve organ damage in LPS-induced septic mice. In the figure, AD is the state of the tissue under the microscope of H&E staining; A is liver tissue; B is spleen tissue; C is lung tissue; D is kidney tissue; EH are schematic diagrams of pathological scores of liver tissue, spleen tissue, lung tissue, and kidney tissue, respectively.
[0050] from Figure 6 As can be seen in A, in the liver tissue of mice, the cells in the Mock group were arranged radially around the central vein, with less inflammatory cell infiltration; the cells in the LPS group and the Vector+LPS group were arranged irregularly near the center of the central vein, with pathological changes such as cell swelling and inflammatory cell infiltration; the DcR3-SUMO+LPS group and the DcR3+LPS group restored the radial arrangement around the central vein, and the cell swelling was alleviated. Figure 6 As can be seen in B, in the spleen tissue, the number of white pulp in the Mock group was relatively large; the number of white pulp in the LPS group and the Vector+LPS group was significantly reduced; the number of white pulp in the DcR3-SUMO+LPS group and the DcR3+LPS group was restored. Figure 6 As can be seen in C, in the lung tissue, the alveolar structure of the Mock group was intact and distributed in a reticular pattern; the alveolar structure of the LPS group and the Vector+LPS group was disordered, not arranged in a reticular pattern, and the alveolar wall structure was significantly thickened; the alveolar structure of the DcR3-SUMO+LPS group and the DcR3+LPS group restored the reticular structure, and the thickening of the alveolar wall structure was improved. Figure 6 As can be seen in D, in the kidney tissue, there was a clear distance between the glomerulus and the renal capsule in the Mock group; there was no distance between the glomerulus and the renal capsule in the LPS group and the Vector+LPS group, and the glomeruli were swollen and accompanied by lymphocyte infiltration; the distance between the glomerulus and the renal capsule in the DcR3-SUMO+LPS group and the DcR3+LPS group was restored, and the glomerular swelling was alleviated. In summary, DcR3-SUMO can effectively improve the organ damage of LPS-induced septic mice.
[0051] The present invention successfully uses the Escherichia coli prokaryotic expression system to express and purify DcR3-SUMO protein in vitro. The DcR3-SUMO can reduce the expression level of inflammatory factors in RAW264.7 and THP1 cells, and can rescue the death of LPS-induced septic mice, reduce the expression level of inflammatory factors in septic mice, and improve tissue and organ damage. The DcR3-SUMO protein of the present invention has anti-inflammatory activity and can inhibit inflammation, indicating that the presence of the His-SUMO sequence does not affect the anti-inflammatory function of DcR3, and DcR3-SUMO also has the ability to treat sepsis.
[0052] The above is only a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several modifications and improvements without departing from the inventive concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. Application of a recombinant DcR3-SUMO protein in a drug for treating sepsis.
2. The use of a recombinant DcR3-SUMO protein in a drug for treating sepsis according to claim 1, characterized in that: The medicine is an injection preparation.
3. The use of a recombinant DcR3-SUMO protein in a drug for treating sepsis according to claim 2, characterized in that: The injection preparation is administered by intraperitoneal infusion.
4. The use of a recombinant DcR3-SUMO protein in a drug for treating sepsis according to claim 1, characterized in that: The nucleic acid sequence of the recombinant DcR3-SUMO protein is shown in SEQ ID NO.
1.
5. The use of a recombinant DcR3-SUMO protein in a drug for treating sepsis according to claim 1, characterized in that: The amino acid sequence of the recombinant DcR3-SUMO protein is shown in SEQ ID NO.2.
Citation Information
Patent Citations
Application of decoy receptor 3 in preparation of medicine for treating sepsis
CN104840945A
